AGT and hypertensive disorder: It suppresses the generation of angiotensin I and II, inhibiting the renin-angiotensin-aldosterone system to reduce blood pressure.549 Phase I studies showed that a single subcutaneous dose of zilebesiran of 200 mg or more considerably decreased serum AGT levels and 24 h ambulatory blood pressure for up to 24 weeks, with only mild injection site reactions observed.550 In Phase II trials (KARDIA-1), zilebesiran reduced systolic blood pressure in all treated patients, with effects lasting 6 months, opening new possibilities for NADs use in treating hypertension and CVDs.551